Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
In development
Reference number: GID-TA11402
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early April 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-June 2025.